Clinical trials using IL-21 as a single agent in melanoma and renal cell carcinoma show that this cytokine is well tolerated and favorable clinical responses have been observed as evidenced by patients in which disease stabilized (206, 207). The gene discussed is IL21; the disease is melanoma.